SCHEMBL15630998

SCHEMBL15630998

CC(=O)Nc1cccc(C(=O)NCC(=O)O)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGER Q15109 1/20 0.47
ITGB3 P05106 1/20 0.47
ITGB1 P05556 1/20 0.47
ITGAV P06756 1/20 0.47
ITGA5 P08648 1/20 0.47
POLB P06746 1/20 0.46
CYP2C19 P33261 1/20 0.46
RAB9A P51151 7/20 0.46
NPC1 O15118 6/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 2/20 0.46
KEAP1 Q14145 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21800978 0.86 CYP2C19 (0.58) ITGB3ITGB1ITGAVITGA5POLB
SCHEMBL12949884 0.80 POLB (0.50) AGERPOLBRAB9ANPC1KDM4E
SCHEMBL9848863 0.79 NPC1 (0.62) POLBCYP2C19RAB9ANPC1KDM4E
SCHEMBL436270 0.77 KEAP1 (0.49) POLBRAB9AKEAP1HPGDGAA
SCHEMBL15630971 0.77 KEAP1 (0.49) POLBRAB9ANPC1KDM4EHSD17B10
SCHEMBL15610699 0.75 NPC1 (0.44) AGERITGB3ITGB1ITGAVITGA5
SCHEMBL15630439 0.75 SMN1; SMN2 (0.46) AGERRAB9ANPC1KDM4EKEAP1
SCHEMBL15630981 0.75 SMN1; SMN2 (0.46) AGERRAB9ANPC1KDM4EKEAP1
SCHEMBL14817806 0.75 ALDH1A1 (0.65) POLBCYP2C19RAB9ANPC1KDM4E
SCHEMBL436284 0.75 KEAP1 (0.57) RAB9AKEAP1ALDH1A1LMNAEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906344-B2 F-18 radiolabeled compounds for diagnosing and monitoring kidney function KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) 2014-12-09 US disclosed
US-20140086837-A1 F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) 2014-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140086837-A1 F-18 RADIOLABELED COMPOUNDS FOR DIAGNOSING AND MONITORING KIDNEY FUNCTION SLCO1B1, SLCO1B3, SLCO2B1 AGER 1136/4885ITGB3 3335/4885ITGB1 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.